Citius Oncology Reports First Revenue of $3.94 Million Following LYMPHIR Launch

Citius Oncology, Inc. reported its financial results for the three months ending December 31, 2025, revealing a revenue of $3.94 million, marking a significant milestone as it represents the company's first revenue following the commercial launch of its oncology immunotherapy product, LYMPHIR (denileukin diftitox). This revenue was generated through agreements with specialty distributors who distribute LYMPHIR to healthcare providers. The company reported a gross profit of approximately $3.15 million, reflecting a gross margin of about 80%. However, Citius Oncology incurred a net loss of $5.53 million for the quarter, a decrease from a net loss of $6.66 million in the same period the previous year.

In terms of operational changes, Citius Oncology's total assets increased to $109.97 million as of December 31, 2025, up from $100.94 million at the end of the previous fiscal quarter. The company's cash and cash equivalents also saw a notable increase, rising to $7.30 million from $3.92 million. The increase in cash was primarily due to a successful equity offering that generated approximately $15.1 million in net proceeds. The company’s total liabilities decreased to $51.56 million, down from $56.08 million, largely due to a reduction in accounts payable and license payable.

Citius Oncology's operational metrics indicate a growing engagement with its product. The company has initiated commercial distribution of LYMPHIR, which is expected to enhance its market presence. The company has also been actively involved in strategic partnerships, including a shared services agreement with Citius Pharmaceuticals, which has historically provided funding and operational support. As of December 31, 2025, Citius Oncology had 88,275,204 shares of common stock outstanding, reflecting its ongoing capital-raising efforts.

Looking ahead, Citius Oncology faces challenges related to its liquidity and the need for additional financing. The company reported a negative working capital of approximately $7.6 million and has indicated that it will require further capital to support operations beyond May 2026. The company plans to continue relying on funding from Citius Pharmaceuticals, pursue equity financing, and generate revenue from LYMPHIR sales. Citius Oncology has engaged Jefferies LLC as its financial advisor to explore strategic alternatives aimed at maximizing shareholder value, although there is no guarantee that additional funding will be secured on favorable terms.

Overall, Citius Oncology's recent financial performance reflects a pivotal moment in its operational trajectory, with the launch of LYMPHIR marking a significant step towards establishing a revenue-generating business model. However, the company must navigate its financial challenges and secure additional funding to sustain its growth and operational objectives in the competitive oncology market.